Cangrelor Use in Routine Practice: A Two-Center Experience

Cangrelor Use in Routine Practice: A Two-Center Experience

Cangrelor is the first and only intravenous P2Y<sub>12</sub>-inhibitor and is indicated when (timely) administration of an oral P2Y<sub>12</sub> inhibitor is not feasible in patients undergoing percutaneous coronary intervention (PCI). Our study evaluated the first years of c...

Full description

Bibliographic Details
Main Authors: Niels M. R. van der Sangen, Ho Yee Cheung, Niels J. W. Verouden, Yolande Appelman, Marcel A. M. Beijk, Bimmer E. P. M. Claessen, Ronak Delewi, Paul Knaapen, Jorrit S. Lemkes, Alexander Nap, M. Marije Vis, Wouter J. Kikkert, José P. S. Henriques
Format: Article
Language:English
Published: MDPI AG 2021-06-01
Series:Journal of Clinical Medicine
Subjects:
cangrelor
antiplatelet therapy
percutaneous coronary intervention
Online Access:https://www.mdpi.com/2077-0383/10/13/2829

Internet

https://www.mdpi.com/2077-0383/10/13/2829

Similar Items